- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07572435
Preliminary Efficacy of a Remote Cardiac Rehabilitation Program in Pediatric Patients With Complex Congenital Heart Disease
6 мая 2026 г. обновлено: Sung Eun Hyun, Seoul National University Hospital
Preliminary Efficacy of a Community-Based Remote Cardiac Rehabilitation Program on Cardiopulmonary Function and Quality of Life in Pediatric Patients With Complex Congenital Heart Disease: A Single Blind, Randomized Controlled Trial
This study aims to evaluate the preliminary efficacy of a 12-week community-based remote cardiac rehabilitation program on cardiopulmonary function and quality of life in pediatric patients (aged 8 to 18 years) with complex congenital heart disease.
Participants will be randomly assigned to either an experimental group receiving the remote cardiac rehabilitation program or a control group receiving the standard of care.
Обзор исследования
Статус
Рекрутинг
Условия
Тип исследования
Интервенционный
Регистрация (Оцененный)
45
Фаза
- Непригодный
Контакты и местонахождение
В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.
Контакты исследования
- Имя: Sungbae Jo Research Professor, Ph.D
- Номер телефона: 82-2-2072-4178
- Электронная почта: sungbaejo@snuh.org
Места учебы
-
-
-
Seoul, Южная Корея, 03080
- Рекрутинг
- Seoul National University Hospital
-
Контакт:
- Sungbae Jo Research Professor, Ph.D
- Номер телефона: 82-2-2072-4178
- Электронная почта: sungbaejo@snuh.org
-
-
Критерии участия
Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.
Критерии приемлемости
Возраст, подходящий для обучения
- Ребенок
- Взрослый
Принимает здоровых добровольцев
Нет
Описание
Inclusion Criteria:
- Aged 8 to 18 years.
- Diagnosed with complex congenital heart disease (e.g., single ventricle, transposition of the great arteries) and have a history of cardiac surgery.
- At least 3 months post-cardiac surgery and maintaining a stable hemodynamic status.
- Capable of utilizing remote programs (mobile apps, video platforms, etc.) in the home environment with technical support from guardians.
- Participant or guardian has agreed to participate and signed the written informed consent form.
- Confirmed to have decreased physical activity level and physical well-being through assessments (Must meet both):
- KIDSCREEN-27 Parent Proxy-report 'Physical well-being' domain T-score of 40 or below.
- Exercise Vital Sign (EVS) survey indicating moderate-to-vigorous physical activity (MVPA) time of less than 420 minutes per week.
Exclusion Criteria:
- Ongoing cardiovascular diseases such as uncontrolled arrhythmia, acute heart failure, myocarditis, or pericarditis.
- Neurological or musculoskeletal disorders that make independent exercise impossible.
- Cognitive impairment that prevents understanding or following the instructions of the remote rehabilitation program.
- Clinical levels of depression or anxiety restricting exercise participation, as determined by the attending physician (assessed via Korean Children's Depression Inventory 2: Self-Report [K-CDI-2:SR] and Revised Children's Manifest Anxiety Scale, Second Edition [RCMAS-2]).
- Inability to cooperate with study tests, such as the Cardiopulmonary Exercise Test (CPET), Electrocardiogram (ECG), and 6-Minute Walk Test (6MWT).
- Currently wearing an artificial pacemaker.
Учебный план
В этом разделе представлена подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Remote Cardiac Rehabilitation Group
Participants randomly assigned to this group will receive a 12-week remote cardiac rehabilitation program followed by a 12-week follow-up period (total 24 weeks).
|
The program consists of supervised remote exercise via ZOOM once a week (approx.
60 minutes, including warm-up, aerobic, resistance, respiratory, and cool-down exercises) and self-directed exercise 3 to 7 times a week.
Biological signals (ECG, heart rate, SpO2) are monitored using wearable devices (mobiCARE, pulse oximeter, and smartwatch).
A respiratory muscle training device (POWERbreathe) is also utilized.
Participants will maintain their usual outpatient care, medications, and standard physical activity guidelines for without the remote structured intervention.
|
|
Активный компаратор: Control Group
Participants randomly assigned to this group will receive the standard of care for 24 weeks.
After the 24-week evaluation, they will be offered a 1-month exercise education program opportunity.
|
Participants will maintain their usual outpatient care, medications, and standard physical activity guidelines for without the remote structured intervention.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in Maximal Oxygen Consumption (VO2 max)
Временное ограничение: Baseline (Week 0), 12 weeks
|
Measured by Cardiopulmonary Exercise Test (CPET) using the OSAKA protocol.
It assesses the maximal amount of oxygen the body can utilize during exercise.
|
Baseline (Week 0), 12 weeks
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in Pediatric Quality of Life Inventory (PedsQL) Total Score
Временное ограничение: Baseline (Week 0), 12 weeks, 24 weeks
|
Health-related quality of life assessed by the PedsQL questionnaire.
Total scores range from 0 to 100, where higher scores indicate a better outcome (higher health-related quality of life).
|
Baseline (Week 0), 12 weeks, 24 weeks
|
|
Cardiac Rehabilitation Program Attendance Rate
Временное ограничение: 12 weeks, 24 weeks
|
Calculated as the number of participated sessions divided by the total number of provided sessions (%).
|
12 weeks, 24 weeks
|
|
Drop-out Rate
Временное ограничение: 12 weeks, 24 weeks
|
Percentage of participants who dropped out related to the intervention
|
12 weeks, 24 weeks
|
|
Change in Physical Activity Level
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
Measured by an accelerometer (GENEActiv) worn for 7 days and smartwatch data.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Global Physical Activity Questionnaire (GPAQ) Score
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
Assesses levels of physical activity in three domains (activity at work/school, travel to and from places, recreational activities) and sedentary behavior.
The Global Physical Activity Questionnaire (GPAQ) calculates physical activity volume in Metabolic Equivalent of Task (MET)-minutes per week, with a minimum value of 0 and no defined maximum limit, where higher values indicate a better outcome (greater physical activity).
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Pediatric Quality of Life Inventory (PedsQL) Parent Proxy-Report Score
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
Assesses health-related quality of life of the pediatric patient from the perspective of the parents or guardians.
Total scores range from 0 to 100, where higher scores indicate a better outcome (higher health-related quality of life).
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Pediatric Quality of Life Inventory (PedsQL) Cardiac Module Score
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
A disease-specific module designed to measure health-related quality of life specifically in pediatric patients with heart disease.
Total scores range from 0 to 100, where higher scores indicate a better outcome (better disease-specific quality of life).
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Pediatric Quality of Life Inventory (PedsQL) Cardiac Module Parent Proxy-Report Score
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
A disease-specific module designed to measure health-related quality of life specifically in parent proxy-report of pediatric patients with heart disease.
Total scores range from 0 to 100, where higher scores indicate a better outcome (better disease-specific quality of life).
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Resilience Scale for Youth (RS-Y) Score
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
Assesses the level of psychological resilience in children and adolescents.
Total scores range from 37 to 185 (based on 37 items), where higher scores indicate a better outcome (greater psychological resilience).
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Child Behavior Checklist (CBCL) Score
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
Evaluates behavioral and emotional problems in children and adolescents, as reported by parents or guardians.
Results are reported as T-scores typically ranging from 28 to 100, where higher scores indicate a worse outcome (more severe behavioral or emotional problems).
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Korean Children's Depression Inventory 2: Self-Report (K-CDI-2:SR) Score
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
A self-report assessment to evaluate the presence and severity of depressive symptoms in children and adolescents.
Scores range from 0 to 56, where higher scores indicate a worse outcome (more severe depressive symptoms).
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Revised Children's Manifest Anxiety Scale, Second Edition (RCMAS-2) Score
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
A self-report instrument designed to assess the level and nature of anxiety in children and adolescents.
Results are reported as scores typically ranging from 0 to 40, where higher scores indicate a worse outcome (greater severity of anxiety).
|
Baseline, 12 weeks, 24 weeks
|
|
Incidence of Adverse Events (Safety)
Временное ограничение: 12 weeks, 24 weeks
|
Proportion and rate of adverse events and serious adverse events occurring during exercise.
|
12 weeks, 24 weeks
|
|
Change in Oxygen Consumption (VO2)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The volume of oxygen consumed per minute during the cardiopulmonary exercise test.
Unit: L/min.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Carbon Dioxide Production (VCO2)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The volume of carbon dioxide produced per minute during the cardiopulmonary exercise test.
Unit: L/min.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Respiratory Exchange Ratio (RER)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The ratio of carbon dioxide production to oxygen consumption during the cardiopulmonary exercise test.
Unit: Ratio
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Minute Ventilation (VE)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The total volume of air inhaled and exhaled per minute during the cardiopulmonary exercise test.
Unit: L/min.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Ventilatory Equivalent for Oxygen (VE/VO2)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The ratio of minute ventilation to oxygen consumption, reflecting ventilatory efficiency.
Unit: Ratio
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Ventilatory Equivalent for Carbon Dioxide (VE/VCO2)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The ratio of minute ventilation to carbon dioxide production, reflecting ventilatory efficiency.
Unit: Ratio
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Oxygen Pulse (O2 Pulse)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The amount of oxygen consumed per heart beat during the cardiopulmonary exercise test.
Unit: mL/beat.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Peripheral Capillary Oxygen Saturation (SpO2)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The blood oxygen saturation level measured via pulse oximetry during the cardiopulmonary exercise test.
Unit: %.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Maximal Heart Rate (HRmax)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The highest heart rate achieved during the cardiopulmonary exercise test.
Unit: beats per minute (bpm).
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Skeletal Muscle Mass measured by Bioelectrical Impedance Analysis (BIA)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The total weight of skeletal muscle in the body measured by bioelectrical impedance analysis.
Unit: kg.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Fat Mass measured by Bioelectrical Impedance Analysis (BIA)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The total weight of fat in the body measured by bioelectrical impedance analysis.
Unit: kg.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Percent Body Fat measured by Bioelectrical Impedance Analysis (BIA)
Временное ограничение: Baseline, 12 weeks, 24 weeks 13.
|
The percentage of total body weight that consists of fat, measured by bioelectrical impedance analysis.
Unit: %.
|
Baseline, 12 weeks, 24 weeks 13.
|
|
Change in Abdominal Fat Ratio measured by Bioelectrical Impedance Analysis (BIA)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The ratio of abdominal fat, evaluated by waist-to-hip circumference ratio via bioelectrical impedance analysis.
Unit: %.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Extracellular Water Ratio measured by Bioelectrical Impedance Analysis (BIA)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The ratio of extracellular water to total body water, measured by bioelectrical impedance analysis.
Unit: %.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Radial Artery Augmentation Index (AIx)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
A measure of arterial stiffness derived from the radial artery pulse wave, standardized to a heart rate of 75 bpm (AIx@75).
Unit: %.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Carotid-femoral Pulse Wave Velocity (c-f PWV)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The speed of the arterial pulse propagating from the carotid to the femoral artery, reflecting arterial stiffness.
Unit: m/s.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Flow-Mediated Dilation (FMD)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The percentage increase in brachial artery diameter following a period of ischemia, assessing endothelial function.
Unit: %.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in 6-Minute Walk Test (6MWT) Distance
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The total distance a participant can walk on a flat, hard surface in exactly 6 minutes.
Unit: meters (m).
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Lower Limb Strength measured by isokinetic dynamometer (Biodex)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The maximum isometric knee extension peak torque measured by an isokinetic dynamometer.
Unit: Newton meters (N.m).
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Lower Limb Muscular Endurance measured by 1-minute squats
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The total number of chair stand squats completed within exactly one minute.
Unit: repetitions.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Upper Limb Strength (Grip Strength)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The maximum isometric handgrip strength measured using a hand dynamometer.
Unit: kg.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Flexibility measured by sit and reach test
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The maximum distance reached forward while sitting with legs extended, assessing lower back and hamstring flexibility.
Unit: cm.
|
Baseline, 12 weeks, 24 weeks
|
|
Change in Maximal Inspiratory Pressure (MIP)
Временное ограничение: Baseline, 12 weeks, 24 weeks
|
The maximum pressure generated during inspiration against an occluded airway, assessing respiratory muscle strength.
Unit: mmH2O.
|
Baseline, 12 weeks, 24 weeks
|
Соавторы и исследователи
Здесь вы найдете людей и организации, участвующие в этом исследовании.
Соавторы
Даты записи исследования
Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.
Изучение основных дат
Начало исследования (Оцененный)
1 мая 2026 г.
Первичное завершение (Оцененный)
31 октября 2029 г.
Завершение исследования (Оцененный)
31 декабря 2029 г.
Даты регистрации исследования
Первый отправленный
23 апреля 2026 г.
Впервые представлено, что соответствует критериям контроля качества
6 мая 2026 г.
Первый опубликованный (Действительный)
7 мая 2026 г.
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
7 мая 2026 г.
Последнее отправленное обновление, отвечающее критериям контроля качества
6 мая 2026 г.
Последняя проверка
1 апреля 2026 г.
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 2511-022-1690
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
НЕ РЕШЕНО
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Нет
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Нет
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .